Form 4 Filing for Avalo Therapeutics, Inc.

This filing reports a Form 4 for Gilla Kaplan, a director at Avalo Therapeutics, Inc. The transaction, dated June 2, 2026, involves the acquisition of 20,100 stock options with a right to buy Common Stock. The options have an exercise price of $13.96 and an expiration date of June 2, 2036. These options vest 100% on the first anniversary of the grant date, contingent upon continued service. Gilla Kaplan acquired these options as a director, and following this transaction, holds 20,100 shares of Common Stock underlying these options.